Takeda Pharmaceutical Co. Ltd. is leading a $125 million investment in Maverick Therapeutics Inc., a company founded with initial financing from MPM Capital that is working to improve the utility of T-cell redirection therapy for the treatment of cancer. The financing, encompassing both equity investment and R&D funding, provides Takeda an exclusive option to buy the company after five years for an undisclosed amount.